Sarepta’s Elevidys Safety Concerns Open Major Opportunity for Solid Biosciences’ (SLDB) SGT-003 in Duchenne Therapy

Solid Biosciences Inc. (NASDAQ:SLDB) is one of the stocks that will double in 2026. On December 4, Needham analyst Gil Blum ...
Yahoo

Sarepta’s Risky Gamble: Gene Therapy Stays on Market Despite FDA Request

When three patients die after taking a cutting-edge drug, most companies hit the brakes. Not Sarepta Therapeutics. The Massachusetts-based biotech company is under fire for refusing a request from the ...
Clinical Trials Arena on MSN

Sarepta terminates Hansa-partnered gene therapy combination trial

Sarepta and Hansa formed the partnership in 2020 to determine if Idefirix could broaden the patient population for Elevidys.
Kalkine Media

Sarepta Therapeutics (NASDAQ:SRPT) Nasdaq Index Tracks Biotech Advancements

Sarepta Therapeutics (NASDAQ:SRPT) leads in genetic therapies, contributing to ongoing discussions surrounding the nasdaq ...
Daily Reporter

Gene therapy maker Sarepta tells FDA it won’t halt shipments despite patient deaths

WASHINGTON (AP) — Drugmaker Sarepta Therapeutics said late Friday it won’t comply with a request from the Food and Drug Administration to halt all shipments of its gene therapy following the death of ...
SFGate

Sarepta will resume gene therapy shipments after FDA review of recent patient death

WASHINGTON (AP) — Shares of beleaguered drugmaker Sarepta Therapeutics jumped in afterhours trading Monday after the company said it would resume shipping its gene therapy for some patients, following ...

What happened when a mom learned a drug to save her baby cost $2 million

A mom was overjoyed when she learned a gene therapy treatment could save her child's life, until she found out no one would cover the $2 million price tag.
Seeking Alpha

Gene therapy maker Sarepta tells FDA it won't halt shipments despite patient deaths

WASHINGTON (AP) — Drugmaker Sarepta Therapeutics (SRPT) said late Friday it won't comply with a request from the Food and Drug Administration to halt all shipments of its gene therapy following the ...